AMG 706

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Histologically or Cytologically Documented Solid Tumors

Conditions

Histologically or Cytologically Documented Solid Tumors

Trial Timeline

Sep 1, 2005 → Feb 1, 2010

NCT ID

NCT01235416

About AMG 706

AMG 706 is a phase 1 stage product being developed by Amgen for Histologically or Cytologically Documented Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT01235416. Target conditions include Histologically or Cytologically Documented Solid Tumors.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01386866	Phase 1	Completed	May 1, 2009	Dec 1, 2010	Advanced Solid Tumors
NCT00360867	Phase 2	Terminated	Dec 1, 2005	Jul 1, 2012	Solid Tumors
NCT00254267	Phase 2	Completed	Nov 1, 2005	Dec 1, 2012	Advanced Gastrointestinal Stromal Tumor
NCT01235416	Phase 1	Completed	Sep 1, 2005	Feb 1, 2010	Histologically or Cytologically Documented Solid Tumors
NCT00121628	Phase 2	Completed	Jul 1, 2005	Oct 1, 2010	Thyroid Cancer
NCT00089960	Phase 2	Completed	Oct 1, 2004	Jun 1, 2008	Gastrointestinal Cancer

Competing Products

2 competing products in Histologically or Cytologically Documented Solid Tumors

See all competitors

Product	Company	Stage	Hype Score
Gefitinib, 5-fluorouracil, leucovorin and radiotherapy	AstraZeneca	Phase 1/2	24
ASA404	Novartis	Phase 1	21